These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31077601)

  • 41. Even Faster Door-to-Alteplase Times and Associated Outcomes in Acute Ischemic Stroke.
    Jung S; Rosini JM; Nomura JT; Caplan RJ; Raser-Schramm J
    J Stroke Cerebrovasc Dis; 2019 Dec; 28(12):104329. PubMed ID: 31607439
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety of air medical transportation after tissue plasminogen activator administration in acute ischemic stroke.
    Chalela JA; Kasner SE; Jauch EC; Pancioli AM
    Stroke; 1999 Nov; 30(11):2366-8. PubMed ID: 10548672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ischaemic stroke: decide rapidly.
    Prescrire Int; 2015 Sep; 24(163):221. PubMed ID: 26417638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stroke Thrombolysis in Patients Taking Ticagrelor -Two Successful Cases and a Review of the Literature.
    Landzberg DR; English S; Frankel M; Navalkele D
    J Stroke Cerebrovasc Dis; 2021 Feb; 30(2):105520. PubMed ID: 33310594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials.
    Xu N; Chen Z; Zhao C; Xue T; Wu X; Sun X; Wang Z
    Drug Des Devel Ther; 2018; 12():2071-2084. PubMed ID: 30013325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
    Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
    Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A practice game changer: Impact of tenecteplase for acute ischemic stroke in a multicenter quality improvement project.
    Noh L; Pham F; Haddad L; Burkhard T; Paletz L; Pech M; Lewis M; Manoukian V; Schlick KH; Song S
    Am J Health Syst Pharm; 2022 Apr; 79(9):e149-e153. PubMed ID: 35037028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke.
    Menon BK; Al-Ajlan FS; Najm M; Puig J; Castellanos M; Dowlatshahi D; Calleja A; Sohn SI; Ahn SH; Poppe A; Mikulik R; Asdaghi N; Field TS; Jin A; Asil T; Boulanger JM; Smith EE; Coutts SB; Barber PA; Bal S; Subramanian S; Mishra S; Trivedi A; Dey S; Eesa M; Sajobi T; Goyal M; Hill MD; Demchuk AM;
    JAMA; 2018 Sep; 320(10):1017-1026. PubMed ID: 30208455
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of alteplase in the very elderly after acute ischemic stroke.
    Yayan J
    Clin Interv Aging; 2013; 8():963-74. PubMed ID: 23950641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidental Thrombotic Thrombocytopenic Purpura during Acute Ischemic Stroke and Thrombolytic Treatment.
    Acır İ; Erdoğan HA; Yayla V; Taşdemir N; Çabalar M
    J Stroke Cerebrovasc Dis; 2018 May; 27(5):1417-1419. PubMed ID: 29196200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thrombolytic Treatment for Ischaemic Stroke: Could the Crisis of Confidence Have Been Avoided by Better Analysis of Trial Data?
    Barer D; Berge E
    Drugs Aging; 2017 Feb; 34(2):79-88. PubMed ID: 28120326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased benefit of alteplase in patients with ischemic stroke and a high body temperature.
    de Ridder I; den Hertog H; van Gemert M; Dippel D; van der Worp B;
    Cerebrovasc Dis; 2013; 35(1):60-3. PubMed ID: 23428998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug treatment of acute ischemic stroke.
    Bansal S; Sangha KS; Khatri P
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):57-69. PubMed ID: 23381911
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety of intravenous thrombolysis in ischemic stroke caused by left atrial myxoma.
    Acampa M; Tassi R; Guideri F; Marotta G; Monti L; Capannini G; Cerase A; Martini G
    Curr Drug Saf; 2011 Nov; 6(5):343-5. PubMed ID: 22424543
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke.
    Huang X; Moreton FC; Kalladka D; Cheripelli BK; MacIsaac R; Tait RC; Muir KW
    Stroke; 2015 Dec; 46(12):3543-6. PubMed ID: 26514192
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determinants for a low dose of alteplase and its relationship to a lower intracerebral bleeding risk in acute ischemic stroke.
    Chen J; Li H; Lei H; Fang S; Yuan Q; Chen Y; Chen D; Chen R; Zhang Y; Wei J; Chen G; Chen Z; Liu N; Du HW
    Int J Med Sci; 2022; 19(12):1762-1769. PubMed ID: 36313231
    [No Abstract]   [Full Text] [Related]  

  • 57. Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients.
    Li W; Lin L; Zhang M; Wu Y; Liu C; Li X; Huang S; Liang C; Wang Y; Chen J; Feng W
    Stroke; 2016 Oct; 47(10):2649-51. PubMed ID: 27608821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
    Yaghi S; Willey JZ; Cucchiara B; Goldstein JN; Gonzales NR; Khatri P; Kim LJ; Mayer SA; Sheth KN; Schwamm LH;
    Stroke; 2017 Dec; 48(12):e343-e361. PubMed ID: 29097489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100 kg on 3-Month Outcomes in Acute Ischemic Stroke.
    Garavaglia J; Sherman J; Yetzer H; Regier M; Smith M
    J Stroke Cerebrovasc Dis; 2017 May; 26(5):1041-1046. PubMed ID: 28129994
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial.
    Chen HS; Cui Y; Zhou ZH; Dai YJ; Li GH; Peng ZL; Zhang Y; Liu XD; Yuan ZM; Jiang CH; Yang QC; Duan YJ; Ma GB; Zhao LW; Wang RX; Sun YL; Shen L; Wang EQ; Wang LH; Feng YF; Wang FY; Zou RL; Yang HP; Wang K; Wang DL; Wang YL;
    JAMA; 2023 Feb; 329(8):640-650. PubMed ID: 36757755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.